Posted by Michael Wonder on 30 Apr 2022
Supernus announces FDA approval of Qelbree for the treatment of attention deficit hyperactivity disorder in adults
29 April 2022 - First novel, non-stimulant option for adults with ADHD in 20 years.
Supernus Pharmaceuticals announced today that the U.S. FDA approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 and older.
The FDA has now approved Qelbree for the treatment of attention deficit hyperactivity disorder in children (starting at age 6), adolescents and adults.
